10b-5 Securities Claims
We have addressed claims of securities fraud related to the potential effect on stock price of the timely disclosure of information concerning a product's underlying safety/efficacy profile. Effectively responding to these kind of claims requires expertise in finance, diverse data sources, biostatistical analysis and other methodologies, and the life sciences industries. Our experience includes:
- Determining the extent of delay in information disclosure
- Identifying the appropriate time window in which alleged damages occurred
- Assessing the number of adversely affected shares
- Calculating the extent to which the share price diverged from its "but-for" path
We have showed that stock price declines associated with the failure of a New Drug Application significantly overstated alleged harm.
We are often called on to analyze stock price volatility and evaluate the alleged loss in value attributable to a specific event or announcement. We have applied economic analyses that rely on financial asset pricing models to test for “abnormal” stock price behavior, accounting for changes in the industry and general stock market.
Our work is frequently published in prestigious peer-reviewed journals and leading business and industry publications.
Securities and Financial Instruments
Successfully addressing claims in pharmaceutical securities litigation requires a combination of financial and industry-specific expertise that is a hallmark of Analysis Group.